# KRDI in Transplant-Eligible MM

> **NCT04430894** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Massachusetts General Hospital** · enrollment: 50 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Carfilzomib
- **DRUG:** Isatuximab
- **DRUG:** Lenalidomide
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT04430894
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-10
- **Primary completion:** 2022-07-30
- **Final completion:** 2026-03-30
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04430894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04430894, "KRDI in Transplant-Eligible MM". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04430894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*